In this single-center prospective study, we will study biological samples of patients undergoing anti-PD-1 immunotherapy to generate effective biomarkers to define the optimal therapeutic strategy and identify potential new immunomodulatory targets in patients with R/M HNSCC. This evidence concerns the gene PDCD1 and head and neck squamous cell carcinoma.